---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344878"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-08-11T20:45:16+00:00"
generated_at: "2026-08-11T20:46:12.718489+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics Q2 2026: cash $494.9M, net loss $44.7M; pipeline milestones on track

## Summary
- Cash, equivalents and marketable securities $494.9M at 6/30/26 vs $360.0M at 12/31/25; runway into 2029.
- Q2 2026 net loss $44.7M ($0.76/share) vs $33.7M ($0.77/share) in Q2 2025; H1 loss $68.9M ($1.22/share).
- R&D expenses Q2 $34.9M (vs $28.1M); G&A $13.1M (vs $8.4M); both up on clinical progress and personnel costs.
- Recognized $20M H1 2026 license revenue from Shionogi milestone for MZE001 (Pompe disease).
- MZE829 HORIZON updated data late 2026/early 2027 (3 cohorts); pivotal trial H1 2027. MZE782 PKU topline 2027; CKD trial H1 2027.

## SEC filing metadata
- accession: 0001193125-26-344878
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-08-11T20:45:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/0001193125-26-344878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344878
- JSON: https://secwatch.observer/filing/0001193125-26-344878.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.